相关实验视频
Updated: Sep 13, 2025

06:47
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
1.1K
功能对血小板聚合的影响:普拉苏格勒和克洛皮多格雷尔的比较研究
Ayane Miyagi1, Toshiki Maeda2, Hisatomi Arima2
1Department of Cardiovascular Medicine, Nephrology and Neurology, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan.
Heart (British Cardiac Society)
|August 1, 2025
概括
在患有慢性病的患者中,普拉苏格勒比克洛皮多格雷尔更快地减少血小板聚合,特别是在治疗的早期. 这一发现强调了功能对抗血小板治疗疗效的重要性.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药理学 药理学是指药理学的学科.
背景情况:
- 慢性病 (CKD) 在冠状动脉疾病 (CAD) 患者中很普遍.
- 慢性瘤显著影响药物分泌和疗效,特别是抗血小板药物.
- 功能修改对于优化CAD患者治疗至关重要.
研究的目的:
- 为了研究功能对血小板聚合抑制的影响.
- 为了比较普拉苏格雷尔与克洛皮多格雷尔在不同程度功能患者中的疗效.
- 评估估计的膜过率 (eGFR) 对抗血小板反应的影响.
主要方法:
- 接受双重抗血小板治疗的164名稳定的CAD患者被随机分配给克洛皮多格雷尔或普拉苏格雷尔.
- 患者被分为两层:eGFR<45和eGFR≥45毫升/分钟/1.73平方米.
- 血小板聚合 (PRU) 在第5天和第30天进行测量;使用共变性分析.
主要成果:
- 与克洛皮多格雷尔相比,普拉苏格勒在EGFR<45组中显示出血小板聚合的更快下降.
- 在第5天 (p=0.036) 在功能障碍组的治疗之间观察到PRU的统计学上显著差异.
- 治疗效果和eGFR之间的相互作用在第5天显著 (p=0.028),表明基于治疗早期功能的药物效应差异.
结论:
- 在患有功能障碍的患者中,prasugrel比克洛皮多格雷尔更快地降低了血小板聚合.
- 这种效应在抗血小板治疗的早期阶段最为明显.
- 需要进行更大,更多样化的研究来证实这些发现,并指导临床实践.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
645
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
645
Formation of the Platelet Plug
7.1K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
7.1K
Factors Affecting Renal Clearance: Renal Impairment
162
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
162
Hepatic Drug Clearance: Effect of Protein Binding
285
Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
285
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
254
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
254
Peripheral Artery Disease III: Interprofessional Care
29
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
29

